Literature DB >> 3640791

Effect of beta-propiolactone--an inhibitor of HTLV III/LAV activity--on immunological analyses.

M J Ball, V Spriggs, P M Sutton, H Chapel.   

Abstract

beta-Propiolactone (BPL) inactivates LAV/HTLV III, the retrovirus associated with acquired immune deficiency syndrome (AIDS). Addition to specimens from patients with suspected AIDS or antibodies to LAV/HTLV III could reduce any occupational risk to laboratory staff. This study demonstrates that BPL treatment does not significantly affect the immunological analyses commonly required on these patients, namely measurements of serum immunoglobulins, complement components C3 and C4 and other serum proteins, detection of autoantibodies and estimations of T lymphocyte subpopulations.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3640791     DOI: 10.1016/0022-1759(86)90324-8

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  4 in total

1.  Use of betapropiolactone to disinfect fresh tissue without impairing antigenicity: method applicable to human immunodeficiency virus (HIV) positive tissue.

Authors:  A J Chaplin; A Heryet; L N Holdsworth; R P Eglin; P R Millard
Journal:  J Clin Pathol       Date:  1989-03       Impact factor: 3.411

2.  Effect of beta propiolactone on specific antibody measurements by ELISA.

Authors:  A E Agbarakwe; S A Misbah; H Griffiths; H M Chapel
Journal:  J Clin Pathol       Date:  1993-04       Impact factor: 3.411

3.  Effect of beta propiolactone viral inactivation on alpha1 antitrypsin values.

Authors:  S J Katona; M Bowen; E R Kaminski
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

4.  Enzyme immunoassay with enhanced specificity for detection of antibodies to Chlamydia trachomatis.

Authors:  J M Ossewaarde; A de Vries; J A van den Hoek; A M van Loon
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.